BTN2-Specific Antibodies for Targeted Immune Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases and prevention of transplant rejection rely on immunosuppressive agents that often have serious side effects or are not entirely effective, highlighting a need for new agents or methods to inhibit immune responses effectively.
Innovation Solution
Development of antibodies specific to BTN2 (BTN2A1 and BTN2A2) that inhibit the production of IFN-γ and TNF-α, cytolytic function, and proliferation of activated Vγ9/Vδ2 T cells, potentially offering a more targeted approach to modulating immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immunosuppressive agents are used to treat autoimmune diseases and prevent transplant rejection, then immune responses are inhibited, but serious side effects occur and effectiveness is limited
Solution Approach 1:
The invention targets a specific molecular complex (BTN2A1-BTN2A2-TCR) involved in T cell activation, rather than using broad-spectrum immunosuppressants. By segmenting the immune suppression mechanism to act only at this specific interaction point, the patent achieves targeted inhibition of pathogenic T cell responses while preserving other immune functions, thereby reducing side effects while maintaining effectiveness.
Solution Approach 2:
The patent uses an antibody as an intermediary molecule to block the interaction between BTN2A1/BTN2A2 and TCR. This intermediary approach allows precise control over T cell activation by preventing the formation of the activating complex, providing a more selective and controllable mechanism compared to conventional immunosuppressive agents that directly interfere with multiple cellular processes.
2Adaptability or versatility
If broad-spectrum immunosuppression is applied to inhibit immune responses, then immune activation is reduced, but specificity and targeted action are lost
Solution Approach 1:
The invention focuses on a specific segment of the immune activation pathway involving BTN2A1, BTN2A2, and TCR interaction. This segmentation allows the therapeutic agent (antibody) to selectively target and modulate only the specific T cell responses mediated through this complex, providing adaptability and versatility in treating autoimmune diseases and transplant rejection without affecting other immune functions.
Solution Approach 2:
The patent employs an antibody with specific binding properties that targets the BTN2A1-BTN2A2-TCR complex at a localized molecular level. This local quality approach ensures that the immunosuppressive effect is concentrated precisely where needed (at the specific T cell activation complex) rather than being distributed broadly across all immune cells, thereby achieving targeted action with high selectivity.
Data Source
AI summary
The present invention relates to antibodies having specificity for BTN2 and uses thereof, in particular for the treatment of cancer.